Which targets are relevant for therapy of acute ischemic stroke?

Stroke

Volumn 30, Issue 7, 1999, Pages 1486-1489

  Heiss, Wolf Dieter ^a,b   Thiel, Alexander ^a   Grond, Martin ^a   Graf, Rudolf ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Cerebral blood flow; Cerebral infarction; Neuroprotection; Penumbra; Reperfusion; Treatment

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; BRAIN SCINTISCANNING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TARGET ORGAN; TREATMENT PLANNING;

EID: 0032984867     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.7.1486     Document Type: Article

References (27)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Grotta J. The current status of neuronal protective therapy: why have all neuronal protective drugs worked in animals but none so far in stroke patients? Cerebrovasc Dis. 1994;4:115-120.
3. Dorman PJ, Counsell CE, Sandercock PAG. Recently developed neuroprotective therapies for acute stroke: a qualitative systematic review of clinical trials. CNS Drugs. 1996;5:457-474.
4. Dyker AG, Lees KR. The rationale for new therapies in acute ischaemic stroke. J Clin Pharm Ther. 1996;21:377-391.
5. del Zoppo GJ, Wagner S, Tagaya M. Trends and future developments in the pharmacological treatment of acute ischaemic stroke. Drugs. 1997; 54:9-38.
6. The European Ad Hoc Consensus Group. Neuroprotection as initial therapy in acute stroke. Cerebrovasc Dis. 1998;8:59-72.
7. Lees KR. Does neuroprotection improve stroke outcome? Lancet. 1998; 351:1447-1448.
8. Choi D. Antagonizing excitotoxicity: a therapeutic strategy for stroke? Mt Sinai J Med. 1998;65:133-138.
9. Kontos HA. Oxygen radicals in cerebral vascular injury. Circ Res. 1985; 57:508-516.
10. Chan PH. Role of oxidants in ischemic brain damage. Stroke. 1996;27: 1124-1129.
11. Chopp M, Zhang ZG. Anti-adhesion molecule and nitric oxide protection strategies in ischemic stroke. Curr Opinion Neurol. 1996;9:68-72.
12. DeGraba TJ. The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy. Neurology. 1998;51:S62-S68.
13. Barinaga M. Stroke-damaged neurons may commit cellular suicide. Science. 1998;281:1302-1304.
14. Endres ME, Namura S, Shimizu-Sasamata M, Waeber C, Zhang L, Gómez-Isla T, Hyman BT, Moskowitz MA. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab. 1998;18:238-247.
15. Heiss W-D, Graf R. The ischemic penumbra. Curr Opin Neurol. 1994; 7:11-19.
16. Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra. Stroke. 1981;12:723-725.
17. Baron JC, von Kummer R, del Zoppo GJ. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke. 1995;26:2219-2221.
18. Fisher M. Characterizing the target of acute stroke therapy. Stroke. 1997; 28:866-872.
19. Wienhard K, Dahlbom M, Eriksson L, Michel Ch, Bruckbauer T, Pietrzyk U, Heiss W-D. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr. 1994;18:110-118.
20. Herscovitch P, Markham J, Raichle ME. Brain blood flow measured with intravenous H2-15O, I: theory and error analysis. J Nucl Med. 1983;24: 782-789.
21. Pietrzyk U, Herholz K, Fink G, Jacobs A, Mielke R, Slansky I, Würker M, Heiss W-D. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med. 1994;35:2011-2018.
22. Stockhausen H-M, Pietrzyk U, Herholz K. Techniken zur Visualisierung funktioneller tomographischer Daten in der klinischen Forschung. In: Arnolds B, Müller H, Saupe D, Tolxdorff T, eds. Digitale Bildverarbeitung in der Medizin. Berlin, Germany: Universitätsklinik Benjamin Franklin; 1996:46-52.
23. Löttgen J, Pietrzyk U, Herholz K, Wienhard K, Heiss W-D. Estimation of ischemic cerebral blood flow using [15O]water and PET without arterial blood sampling. In: Carson RE, Daube-Witherspoon ME, Herscovitch P, eds. Quantitative Functional Brain Imaging With Positron Emission Tomography. San Diego, Calif: Academic Press; 1998:151-154.
24. Baron JC, Rougemont D, Soussaline F, Bustany P, Crouzel C, Bousser MG, Comar D. Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: a positron tomography study. J Cereb Blood Flow Metab. 1984;4: 140-149.
25. Powers WJ, Grubb RL Jr, Darriet D, Raichle ME. Cerebral blood flow and cerebral metabolic rate of oxygen requirements for cerebral function and viability in humans. J Cereb Blood Flow Metab. 1985;5:600-608.
26. Hakim AM, Evans AC, Berger L, Kuwabara H, Worsley K, Marchal G, Beil C, Pokrupa R, Diksic M, Meyer E, Gjedde A, Marrett S. The effect of nimodipine on the evolution of human cerebral infarction studied by PET. J Cereb Blood Flow Metab. 1989;9:523-534.
27. Sherman DG. The Enlimomab Acute Stroke Trial: final results. Neurology. 1997;48:S33. Abstract.